kand567
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 17, 2020 (NCT06030375)
Timeline
Indications
Mechanism of action
- C-X3-C chemokine receptor 1INHIBITOR
CX3CR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06087289 | Phase 1/Phase 2 (Phase 2) | Apr 20, 2023 | Kancera AB, Karolinska Institute, Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
| NCT06012565 | Phase 2 | Oct 11, 2020 | Kancera AB, Novakand Pharma AB |
| NCT06030375 | Phase 1 | Feb 17, 2020 | Clinical Research Services Turku, Kancera AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kancera AB | For profit | 3 | 3 | 2 | 2020 |
| Clinical Research Services Turku | For profit | 1 | 0 | 1 | 2020 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Novakand Pharma AB | For profit | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1